References
1 Oza VS, Stringer T, Campbell C, Hinds B, Chamlin SL, Frieden IJ, Shah
S. Congenital-type juvenile xanthogranuloma: A case series and
literature review. Pediatr Dematol 2018;35:582-587.
2 Maeda M, Morimoto A, Shioda Y, Asano T, Koga Y, Nakazawa Y, Kanegane
H, Kudo K, Ohga S, Ishii E, Histiocytosis Study Group of Japanese
Society of Pediatric Hematology/Oncology. Long-term outcomes of children
with extracutaneous juvenile xanthogranulomas in Japan. Pediatr Blood
Cancer 2020;67(7):e28381.doi:10.1002/pbc.28381.
3 Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi
J, Kin E, Cohen-Aubar F, Lee SC-W, Gao Y, Micol JB, Campbell P, Walsh
MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe
J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl
WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block
J, Heritier S, Donadieu J, Solit DB, Hyman DM, Baselga J, Janku F,
Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA,
Abdel-Wahab O. Diverse and targetable kinase alterations drive
histiocytic neoplasm. Cancer Discov 2016;6:154-165.
4 Durham BH, Rodrigo EL, Picarsic J, Abramson D, Rotemberg V, Munck SD,
Pannecoucke E, Lu SX, Pastore A, Toshimi A, Mandelker D, Ceyhan-Birosy
O, Ulaner GA, Walsh M, Yabe M, Petrova-Drus K, Arcila ME, Ladanyi M,
Solit DB, Berger MF, Hyman DM, Lacouture ME, Erickson C, Saganty R, Ki
M, Dunkel IJ, Lopez VSM, Mora J, Haroche J, Emile JF, Decaux O,
Geissmann F, Savvider SN, Drilon A, Diamond EL, Abdel-Wahab O.
Activating mutations in CSF1R and additional recepter tyrosine kinase in
histiocytic neoplasms. Nat Med 2019;25:1839-1842.
5 Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman
DL, Look AT. Fusion of a kinase gene, ALK, to a nucleolar pritein gene,
NPM, in non-Hodkin’s lymphoma. Science 1994;263:1281-1284.
6 Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S,
Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S,
Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H.
Identification of the tranforming EML4-ALK fusion gene in non-small-cell
lung cancer. Nature 2007;448:561-566.
7 Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Imamura K, Takada S,
Ueno T, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H.
KIF5B-ALK, a novel fusion oncokinase identified by an
immunohistochemistry-based diagnostic system for ALK-positive lung
cancer. Clin Cancer Res 2009;15:3143-3149.
8 Wolter NE, Ngan Bo, Whitlock JA, Dickson BC, Propst EJ. Atypical
juvenile histiocytosis with novel KIF5B-ALK gene fusion mimicking
subglottic hemangioma. Int J Pediatr Otorhinolaryngol 2019
Nov;125:109585. doi: 10.1016/j.ijporrl.2019.07.010.Epub 2019 Jul 13.
9 Lucas CHG, Gilani A, Solomon DA, Liang X, Maher OM, Chamyan G,
Kleinschmidt-Demasters BK, Perry A. ALK-positive histiocytosis with
KIF5B-ALK fusion in the central nervous system. Acta Neuropathol
2019;138:335-337.
10 Kashima J, Yoshida M, Jimbo K, Izutsu K, Ushiku T, Yonemori K,
Yoshida A. AKL-positive Histiocytosis of the breast: A Clicopathologic
Study Highlighting Spindle Cell Histology. Am J Surg Pathol
2021;45:347-355.
11 Chang KTE, Tay AZE, Kuick CH, Chen H, Algar E, Taubenheim N, Campbell
J, Mechinaud F, Campbell M, Super L, Chantranuwat C, Yuen ST, Chan JKC,
Chow CW. ALK-positive histiocytosis: an expanded clinicopathologic
spectrum and frequent presence of KIF5B-ALK fusion. Mod Pathol
2019;32:598-608.
12 Ross JS, Ali SM, Fasa O, Block J, Pal S, Elvin JA, Schrock AB, Suh J,
Nozard S, Kim S, Lee HJ, Sheeham CE. Jones DM, Vergilio JA, Ramkissoon
S, Severson E, Daniel S, Fabrizio D, Framton G, Miller VA, Stephens PJ,
Gay LM. ALK fusions in a wide variety of tumor types respond to anti-ALK
targeted therapy. Oncologist 2017;22:1444-1450.
13 Greengard E, Mosse YP, Liu X, Minard CG, Reid JM, Voss S, Wilner K,
Fox E, Balis F, Blaney SM, Adamson PC, Weigel BJ. Safety, tolerability
and pharmacokinetics of crizotiniv in combination with cytotoxic
chemotherapy for pediatric patients with refractory solid tumors or
anaplastic large cell lymphoma (ALCL): a Children’s Oncology Group
phase1 consortium study (ADVL1212). Cancer Chemother Pharmacol
2020;86:829-840.
14 Foster JH, Voss SD, Hall DC, Minard CG, Balis FM, Wilner K, Berg SL,
Fox E, Adamson PC, Blaney S, Weigel BJ, Mosse YP. Activity of crizotinib
in patients with ALK-aberrant relapsed/refractory neuroblastoma: A
Children’s Oncology Goup Study (ADVL0912). Clin Cancer Res 2021 Feb
10;clincanres.4224.2020.
doi: 10.1158/1078-0432.CCR-20-4224.
15 Fukano R, Mori T, Sekimizu M, Choi I, Kada A, Saito AM, Asada R,
Takeuchi K, Terauchi T, Tateishi U, Horibe K, Nagai H. Alectinib for
relapsed or refractory anaplastic lymphoma kinase-positive anaplastic
large cell lymphoma: An-open label phase II trial. Cancer Sci
2020;111:4540-4547.
16. Takita J. The role of anaplastic lymphoma kinase in pediatric
cancers. Cancer Sci 2017;108:1913-1920.
17 Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Perol M, Wrona A,
Novello S, Rosell R, Zeaiter A, Liu T, Nuesch E, Balas B, Camidge DR.
Alectinib versus crizotinib in treatment-naïve anaplastic lmphoma
kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results
from the ALEX study. Ann Oncol 2018;29:2214-2222.
18 Deilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol
2019 Nov 1;30(Suppl_8):viii23-viii30. doi: 10.1093/annonc/mdz282.
19 Drilon A, Siena S, Ou SHI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago
AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G,
Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli
A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski
K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS,
Shaw AT, Braud FGD. Safety and antitumor activity of the multitargeted
Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two
Phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov.
2017;7:400-409.
20 Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J.
Descriptive epidemiology of childhood langerhance cell histiocytosis in
France, 2000-2004. Pediatr Blood Cancer 2008;51:71-75.